1 – 88 of 88
- show: 250
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2023
-
Mark
Sex differences in disease progression in Alzheimer patients with different concomitant medications.
2023) 17th International Conference on Alzheimer's and Parkinson's Diseases (AD/PD 2023)(
- Contribution to conference › Abstract
-
Mark
Rates of Progression in Patients with Alzheimer’s Disease Depending on Apolipoprotein E Genotype and Concomitant Medications.
2023) 16th Clinical Trials on Alzheimer's Disease Conference(
- Contribution to conference › Poster
- 2022
-
Mark
Interaction effect of sex and onset of Alzheimer’s disease—rates of progression and prognosis.
2022) 16th International Conference on Alzheimer's and Parkinson's Diseases (AD/PD 2022)(
- Contribution to conference › Abstract
-
Mark
Sex differences between early- and late-onset Alzheimer’s disease.
2022) The Kock Foundation International Symposium on Osteoarthritis & Alzheimer's disease 2022(
- Contribution to conference › Abstract
-
Mark
Biomarkörer i cerebrospinalvätska – samband med tid till särskilt boende och död i Alzheimers sjukdom
(
- Contribution to specialist publication or newspaper › Specialist publication article
- 2021
-
Mark
Predictors of mortality in patients with different apolipoprotein E genotypes—a 20-year follow-up of Alzheimer’s disease.
2021) 15th International Conference on Alzheimer's and Parkinson's Diseases (AD/PD 2021)(
- Contribution to conference › Abstract
-
Mark
The Influence of Level of Education on Instrumental Activities of Daily Living in Patients with Alzheimer’s Disease.
2021) 14th Clinical Trials on Alzheimer's Disease Conference(
- Contribution to conference › Poster
-
Mark
Cerebrospinal Fluid Biomarker Levels as Markers for Nursing Home Placement and Survival Time in Alzheimer's Disease
(
- Contribution to journal › Article
-
Mark
Differences in Dementia Care Between Swedish-Born and Foreign-Born from Countries with Different Country Level Socioeconomic Position : A Nationwide Register-Based Study
(
- Contribution to journal › Article
- 2020
-
Mark
The interaction effect of sex and apolipoprotein E genotype in Alzheimer’s disease—rates of progression and prognosis.
2020) Advances in Alzheimer's and Parkinson's Therapies (AAT-AD/PD) Focus Meeting 2020(
- Contribution to conference › Abstract
-
Mark
Cerebro-spinal fluid biomarker levels : phosphorylated tau (T) and total tau (N) as markers for rate of progression in Alzheimer's disease
(
- Contribution to journal › Article
-
Mark
Fosforylerat tau och totalt tau i cerebrospinalvätska vid Alzheimers sjukdom
(
- Contribution to specialist publication or newspaper › Specialist publication article
- 2019
-
Mark
Survival among the older adults with clinical signs of Lewy body dementia in 40 Swedish nursing homes : A 6-year follow-up study
(
- Contribution to journal › Article
-
Mark
Sex differences in predictors of mortality in patients with Alzheimer’s disease – A 20-year follow-up.
2019) 14th International Conference on Alzheimer's and Parkinson's Diseases (AD/PD 2019)(
- Contribution to conference › Abstract
-
Mark
Bättre behandlad Alzheimers sjukdom kan öka tiden att bo hemma
(
- Contribution to specialist publication or newspaper › Specialist publication article
-
Mark
Sex differences in predictors of cognitive and functional outcomes in patients with Alzheimer’s disease.
2019) 12th Clinical Trials on Alzheimer’s Disease Conference(
- Contribution to conference › Poster
-
Mark
Prognostic regression models of life expectancy after diagnosis of Alzheimer’s disease – a 20-year follow-up.
2019) Alzheimer's Association International Conference (AAIC), 2019(
- Contribution to conference › Poster
- 2018
-
Mark
Psychotropic and anti-dementia treatment in elderly persons with clinical signs of dementia with Lewy bodies : A cross-sectional study in 40 nursing homes in Sweden
(
- Contribution to journal › Article
-
Mark
Short-term response to cholinesterase inhibitors in Alzheimer’s disease delays time to nursing home placement
(
- Contribution to journal › Article
-
Mark
Cerebrospinal fluid biomarker levels: Total tau and phosphorylated tau as markers for rate of progression in Alzheimer’s disease.
2018) Advances in Alzheimer’s and Parkinson’s Therapies (AAT-AD/PD) Focus Meeting 2018(
- Contribution to conference › Abstract
-
Mark
Predictors of mortality in early- versus late-onset Alzheimer’s disease – an 18-year follow-up.
2018) Alzheimer’s Association International Conference (AAIC), 2018(
- Contribution to conference › Poster
- 2017
-
Mark
Early- versus late-onset Alzheimer's disease in clinical practice : Cognitive and global outcomes over 3 years
(
- Contribution to journal › Article
-
Mark
Equity in dementia care focusing on immigrants in Sweden: a nationwide register-based study.
2017) 10th European Public Health Conference (EPH) In European Journal of Public Health 27(suppl_3). p.51-51(
- Contribution to journal › Published meeting abstract
-
Mark
Levels of cerebrospinal fluid biomarkers total tau and phosphorylated tau do not predict survival time after diagnosis of Alzheimer’s disease – An 18-year follow-up.
2017) 10th Clinical Trials Conference on Alzheimer’s Disease(
- Contribution to conference › Poster
-
Mark
Response to the Letter From Abid Iraqi, MD, CMD and Terry Hughes, RN, CS
(
- Contribution to journal › Letter
-
Mark
The outcomes of different assessment scales can predict survival in patients with Alzheimer’s disease
2017) 13th International Conference on Alzheimer's and Parkinson's Diseases (AD/PD 2017) In Neurodegenerative Diseases 17(Suppl. 1). p.27-27(
- Contribution to journal › Published meeting abstract
-
Mark
Early- versus late-onset Alzheimer disease : Long-term functional outcomes, nursing home placement, and risk factors for rate of progression.
(
- Contribution to journal › Article
-
Mark
The course and end-points of Alzheimer’s disease according to sociodemographics, apolipoprotein E genotype and cognitive ability.
2017) Alzheimer's Association International Conference (AAIC), 2017(
- Contribution to conference › Poster
-
Mark
Dementia with Lewy Body (DLB) Symptoms Hidden within the Diagnosis “Dementia Not Otherwise Specified” a Cross-Sectional Study in 40 Swedish Nursing Homes.
2017) Alzheimer's Association International Conference (AAIC), 2017(
- Contribution to conference › Poster
- 2016
-
Mark
Mild versus moderate stages of Alzheimer's disease: three-year outcomes in a routine clinical setting of cholinesterase inhibitor therapy.
(
- Contribution to journal › Article
-
Mark
Short-term response to cholinesterase inhibitors in Alzheimer’s disease delays time to nursing home placement.
2016) 14th International Athens/Springfield Symposium on Advances in Alzheimer Therapy In Neurobiology of Aging 39(Suppl. 1). p.2-2(
- Contribution to journal › Published meeting abstract
-
Mark
Cholinesterase inhibitors do not alter the length of stay in nursing homes among patients with Alzheimer's disease : A prospective, observational study of factors affecting survival time from admission to death.
(
- Contribution to journal › Article
-
Mark
Cholinesterase inhibitor therapy does not affect time spent in nursing homes in patients with Alzheimer’s disease.
2016) Alzheimer’s Association International Conference 2016(
- Contribution to conference › Poster
-
Mark
Prevalence of Dementia With Lewy Body Symptoms : A Cross-Sectional Study in 40 Swedish Nursing Homes
(
- Contribution to journal › Article
-
Mark
Early- versus Late-Onset Alzheimer’s Disease—Differences in Functional Impairment.
2016) 9th Clinical Trials Conference on Alzheimer’s Disease(
- Contribution to conference › Poster
- 2015
-
Mark
Longitudinal Associations between Survival in Alzheimer's Disease and Cholinesterase Inhibitor Use, Progression, and Community-Based Services.
(
- Contribution to journal › Article
-
Mark
Various measures of progression predicting mortality in Alzheimer’s disease.
2015) Alzheimer’s Association International Conference (AAIC), 2015 In Alzheimer's & Dementia 11(7 Suppl.). p.293-294(
- Contribution to journal › Published meeting abstract
-
Mark
Mild cognitive impairment and deficits in instrumental activities of daily living: a systematic review.
(
- Contribution to journal › Scientific review
-
Mark
Various outcomes of cholinesterase inhibitor treatment influence survival of patients with Alzheimer’s disease.
2015) 12th International Conference on Alzheimer`s and Parkinson`s Diseases (AD/PD 2015)(
- Contribution to conference › Poster
-
Mark
Lack of orthostatic symptoms in dementia patients with orthostatic hypotension.
(
- Contribution to journal › Article
- 2014
-
Mark
Response to cholinesterase inhibitors affects lifespan in Alzheimer's disease.
(
- Contribution to journal › Article
-
Mark
Solitary living in Alzheimer's disease over 3 years: association between cognitive and functional impairment and community-based services.
(
- Contribution to journal › Article
-
Mark
Risk Factors That Affect Life Expectancy in Alzheimer's Disease: A 15-Year Follow-Up.
(
- Contribution to journal › Article
-
Mark
Factors that affect life-span in mild versus moderate Alzheimer’s disease.
2014) 13th International Geneva/Springfield Symposium on Advances in Alzheimer Therapy In Neurobiology of Aging 35(Suppl. 1). p.25-25(
- Contribution to journal › Published meeting abstract
-
Mark
Cerebral inflammation is an underlying mechanism of early death in Alzheimer's disease: a 13-year cause-specific multivariate mortality study.
(
- Contribution to journal › Article
-
Mark
The effect of functional capacity and concomitant medications on life expectancy in Alzheimer’s disease.
2014) Alzheimer’s Association International Conference (AAIC), 2014(
- Contribution to conference › Poster
-
Mark
Early- versus Late-onset Alzheimer’s Disease—3-year Outcomes of Cholinesterase Inhibitor Treatment in Routine Clinical Practice.
2014) 7th Clinical Trials Conference on Alzheimer’s Disease (CTAD)(
- Contribution to conference › Poster
-
Mark
Prevalence of Lewy body dementia and neuroleptic treatment in nursing homes in Malmö, Sweden.
2014) Alzheimer’s Association International Conference (AAIC), 2014(
- Contribution to conference › Poster
- 2013
-
Mark
Progression of mild Alzheimer's disease: knowledge and prediction models required for future treatment strategies.
(
- Contribution to journal › Article
-
Mark
Evaluation of Systolic and Diastolic Hypotension in Dementia with Lewy Bodies and Alzheimer’s Disease.
(
- Contribution to journal › Article
-
Mark
A longitudinal study of risk factors for community-based home help services in Alzheimer's disease: the influence of cholinesterase inhibitor therapy
(
- Contribution to journal › Article
-
Mark
Prediction Models for Assessing Long-Term Outcome in Alzheimer's Disease: A Review.
(
- Contribution to journal › Scientific review
-
Mark
Living Alone in Alzheimer’s Disease—The Influence of Functional Impairment.
2013) 6th Clinical Trials Conference on Alzheimer’s Disease (CTAD)(
- Contribution to conference › Poster
-
Mark
Mild versus Moderate Stage of Alzheimer’s Disease—Three-year Outcomes of Cholinesterase Inhibitor Therapy in a Routine Clinical Setting.
(
- Contribution to conference › Abstract
-
Mark
Dose and plasma concentration of galantamine in Alzheimer's disease - clinical application
(
- Contribution to journal › Article
-
Mark
Three-year outcome of rivastigmine treatment in Alzheimer's disease in a routine clinical setting.
2013) 11th International Conference on Alzheimer’s & Parkinson’s Diseases (AD/PD 2013)(
- Contribution to conference › Poster
-
Mark
Instrumental Activities of Daily Living in Alzheimer's Disease.
2013) European Alzheimer's Disease Consortium (EADC) Meeting(
- Contribution to conference › Other
- 2012
-
Mark
Comparison of Brief Cognitive Tests and CSF Biomarkers in Predicting Alzheimer's Disease in Mild Cognitive Impairment: Six-Year Follow-Up Study.
(
- Contribution to journal › Article
-
Mark
Functional response to cholinesterase inhibitor therapy in a naturalistic Alzheimer's disease cohort
(
- Contribution to journal › Article
-
Mark
Disease progression and costs of care in Alzheimer's disease patients treated with donepezil: a longitudinal naturalistic cohort.
(
- Contribution to journal › Article
-
Mark
Alzheimer’s disease with normal CSF biomarkers.
2012) 12th International Stockholm/Springfield Symposium on Advances in Alzheimer Therapy(
- Contribution to conference › Poster
-
Mark
Risk factors for community-based home help services among patients with Alzheimer’s disease.
2012) 21st Nordic Congress of Gerontology(
- Contribution to conference › Poster
- 2011
-
Mark
Long Term Outcome and Prediction Models of Cognition, Activities of Daily Living and Nursing Home Placement in Alzheimer’s Disease with Cholinesterase Inhibitor Treatment
(
- Thesis › Doctoral thesis (compilation)
-
Mark
Association between Subcortical Lesions and Behavioral and Psychological Symptoms in Patients with Alzheimer's Disease.
(
- Contribution to journal › Article
-
Mark
Quality of Life and the Effect of Memantine in Dementia with Lewy Bodies and Parkinson's Disease Dementia.
(
- Contribution to journal › Article
-
Mark
Risk Factors for Nursing Home Placement in Alzheimer's Disease: A Longitudinal Study of Cognition, ADL, Service Utilization, and Cholinesterase Inhibitor Treatment.
(
- Contribution to journal › Article
-
Mark
Galantamine treatment in Alzheimer's disease: response and long-term outcome in a routine clinical setting.
(
- Contribution to journal › Article
-
Mark
Predictors of long-term cognitive outcome in Alzheimer's disease.
(
- Contribution to journal › Article
-
Mark
Long-term Outcome and Prediction Models of Activities of Daily Living in Alzheimer Disease With Cholinesterase Inhibitor Treatment.
(
- Contribution to journal › Article
-
Mark
The long-term cognitive outcomes of Alzheimer’s disease — influence of APOE genotype, NSAID therapy, and cholinesterase inhibitor treatment.
2011) 10th International Conference on Alzheimer’s & Parkinson’s Diseases (AD/PD 2011)(
- Contribution to conference › Poster
- 2010
-
Mark
A Quick Test of cognitive speed is sensitive in detecting early treatment response in Alzheimer's disease
(
- Contribution to journal › Article
-
Mark
Plasma concentration of galantamine - influence of dose and body mass index in Alzheimer’s disease.
2010) 11th International Geneva/Springfield Symposium on Advances in Alzheimer Therapy(
- Contribution to conference › Poster
- 2009
-
Mark
Long-term rivastigmine treatment in a routine clinical setting.
(
- Contribution to journal › Article
-
Mark
Risk Factors for Nursing Home Placement in Cholinesterase Inhibitor Treated Naturalistic Alzheimer Patients.
2009) 9th International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD)(
- Contribution to conference › Poster
-
Mark
Medial Temporal Lobe Atrophy Increases the Specificity of Cerebrospinal Fluid Biomarkers in Alzheimer Disease with Minor Cerebrovascular Changes.
(
- Contribution to journal › Article
- 2008
-
Mark
Predicting Long-Term Cognitive Outcome with New Regression Models in Donepezil-Treated Alzheimer Patients in a Naturalistic Setting.
(
- Contribution to journal › Article
-
Mark
Usefulness of computed tomography linear measurements in diagnosing Alzheimer's disease.
(
- Contribution to journal › Article
- 2007
-
Mark
Donepezil in Alzheimer's disease: what to expect after 3 years of treatment in a routine clinical setting.
(
- Contribution to journal › Article
-
Mark
Alzheimer's disease - Safety and dropout in long-term galantamine treatment in a routine clinical setting
(
- Chapter in Book/Report/Conference proceeding › Paper in conference proceeding
-
Mark
Activities of Daily Living – Outcome During Three Years in Donepezil Treated Alzheimer Patients.
2007) IPA (International Psychogeriatric Association) 2007 Osaka Silver Congress(
- Contribution to conference › Poster
-
Mark
Activities of daily living - Outcome during two years in galantamine treated Alzheimer patients
(
- Chapter in Book/Report/Conference proceeding › Paper in conference proceeding
-
Mark
Three-year outcome of Galantamine treatment in Alzheimer’s disease in a routine clinical setting.
2007) IPA (International Psychogeriatric Association) 2007 Osaka Silver Congress(
- Contribution to conference › Poster
- 2006
-
Mark
Two-year outcome of Galantamine treatment in Alzheimer’s disease in a routine clinical setting.
2006) 9th International Geneva/Springfield Symposium on Advances in Alzheimer Therapy(
- Contribution to conference › Poster
-
Mark
New regression models for long-term cognitive change in Donepezil treated Alzheimer patients.
2006) 9th International Geneva/Springfield Symposium on Advances in Alzheimer Therapy(
- Contribution to conference › Poster
-
Mark
2-års resultat av rivastigmin (Exelon®) behandling vid Alzheimers sjukdom i klinisk vardag.
2006) Läkarstämman 2006(
- Contribution to conference › Poster
- 2005
-
Mark
Analysis of the heterogeneity in treatment response to Donepezil in Alzheimer’s disease conclusions from the Swedish Alzheimer Treatment Study Group.
(
- Contribution to conference › Poster
- 2004
-
Mark
Five-Year Outcome of Cholinergic Treatment of Alzheimer's Disease: Early Response Predicts Prolonged Time until Nursing Home Placement, but Does Not Alter Life Expectancy.
(
- Contribution to journal › Article
- 1996
-
Mark
Prevalence of thyroid hormone abnormalities in elderly patients with symptoms of organic brain disease.
(
- Contribution to journal › Article